Thrivent Financial for Lutherans’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-20,217
Closed -$1.03M 2635
2025
Q4
$1.03M Sell
20,217
-689
-3% -$35.2K ﹤0.01% 1914
2025
Q3
$1.16M Sell
20,906
-24,224
-54% -$1.42M ﹤0.01% 1695
2025
Q2
$3.1M Sell
45,130
-2,769
-6% -$188K 0.01% 1068
2025
Q1
$5.21M Sell
47,899
-72,736
-60% -$6.01M 0.01% 819
2024
Q4
$11.5M Sell
120,635
-8,965
-7% -$969K 0.02% 613
2024
Q3
$15.4M Sell
129,600
-660,825
-84% -$88.1M 0.03% 540
2024
Q2
$113M Sell
790,425
-545,344
-41% -$72.3M 0.23% 101
2024
Q1
$172M Sell
1,335,769
-67,624
-5% -$8.05M 0.34% 53
2023
Q4
$145M Buy
1,403,393
+359,798
+34% +$35.6M 0.32% 64
2023
Q3
$94.9M Buy
1,043,595
+451,797
+76% +$39.8M 0.23% 123
2023
Q2
$47.9M Buy
591,798
+15,458
+3% +$1.26M 0.11% 242
2023
Q1
$45.9M Sell
576,340
-461,290
-44% -$32.7M 0.11% 238
2022
Q4
$70.2M Sell
1,037,630
-507,742
-33% -$29.8M 0.18% 156
2022
Q3
$77M Buy
1,545,372
+133,572
+9% +$7.16M 0.21% 125
2022
Q2
$78.7M Sell
1,411,800
-291,392
-17% -$16.2M 0.21% 120
2022
Q1
$94.6M Buy
1,703,192
+60,052
+4% +$3.08M 0.19% 136
2021
Q4
$92M Buy
1,643,140
+299,794
+22% +$16.2M 0.18% 146
2021
Q3
$64.5M Sell
1,343,346
-454,168
-25% -$22M 0.13% 193
2021
Q2
$75.3M Buy
1,797,514
+78,076
+5% +$3.03M 0.15% 168
2021
Q1
$58M Buy
1,719,438
+133,402
+8% +$4.75M 0.13% 200
2020
Q4
$55.4M Buy
1,586,036
+122,136
+8% +$4.22M 0.13% 198
2020
Q3
$50.8M Buy
1,463,900
+12,812
+0.9% +$427K 0.14% 184
2020
Q2
$47.5M Buy
+1,451,088
New +$46.3M 0.14% 175
2013
Q3
Sell
-13,000
Closed -$201 1584
2013
Q2
$201 Buy
+13,000
New +$216K ﹤0.01% 1438

Other funds holding NVO

Thrivent Financial for Lutherans's NVO Position: Q1 2026 in Review

Thrivent Financial for Lutherans sold out of Novo Nordisk (NVO) in Q1 2026, closing a stake of 20,217 shares — an estimated $1.03M sold.

Thrivent Financial for Lutherans first reported a position in NVO in Q2 2013 and held it in 24 quarters. The position peaked at $172M in Q1 2024. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Thrivent Financial for Lutherans reported no remaining Novo Nordisk position as of Q1 2026 after selling out during the quarter.
  • Thrivent Financial for Lutherans sold 20,217 Novo Nordisk shares in Q1 2026, an estimated $1.03M.
  • Thrivent Financial for Lutherans first reported a position in Novo Nordisk in Q2 2013 and held it in 24 quarters.
  • Thrivent Financial for Lutherans's Novo Nordisk position peaked at $172M in Q1 2024.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Thrivent Financial for Lutherans's 13F filing for Q1 2026, filed 1 May 2026.